CEO Roundtable
The Emerging Specialty Pharma-Biotech Goes Commercial
Thursday, October 20
8:15 a.m. - 9:15 a.m.
Pacific Heights
With the industry maturing toward ever more late-stage products, many biotechnology companies have chosen to commercialize themselves with internally-developed or in-licensed products. How do companies evaluate build versus partner decisions, decide to forward integrate versus wait for pipeline maturation, and what are common pitfalls and hallmarks of success? Finally, how do investors evaluate different business models and deal economics?
Moderator:
- Matthew Plunkett, PhD, Director, Healthcare Investment Banking, CIBC World Markets
Panelists:
- John L. Higgins, Chief Financial Officer and Executive Vice President, Finance and Administration and Corporate Development, Connetics Corporation
- Donald Santel, Chief Executive Officer, CoTherix, Inc.
- Lauren Silvernail, Chief Financial Officer and Vice President of Corporate Development, ISTA Pharmaceuticals, Inc.
- Dan Welch, CEO, InterMune